Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma
Figure 1
Month of diagnosis of patient cohorts. Time line of patient accrual to BEV and No-BEV groups as a function of month of GBM diagnosis. Dot plot indicates month of diagnosis. Using 1/1/2005 as Time 0, there is a statistically but not clinically significant difference in dates of diagnosis.